Agomelatine: A narrative review

European Neuropsychopharmacology

Volumn 21, Issue SUPPL.4, 2011, Pages

  Demyttenaere, Koen ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Agomelatine; Major depressive disorder; Treatment efficacy

Indexed keywords

AGOMELATINE; FLUOXETINE; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; PAROXETINE; PLACEBO; SEROTONIN 2C RECEPTOR; SERTRALINE; VENLAFAXINE;

ACUTE DISEASE; AMINOTRANSFERASE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LIVER FUNCTION TEST; LIVER INJURY; MAJOR DEPRESSION; PATIENT MONITORING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; SYMPTOM; WEIGHT GAIN;

ACETAMIDES; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; COMPARATIVE EFFECTIVENESS RESEARCH; DEPRESSIVE DISORDER, MAJOR; HUMANS; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE;

EID: 80052849856     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2011.07.004     Document Type: Review

References (35)

1. Bauer M., Tharmanathan P., Volz H.P., Moeller H.J., Freemantle N. The effects of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis. Eur. Arch. Psychiatry Clin. Neurosci. 2009, 259:172-185.
2. Cipriani A., Furukawa T.A., Salanti G., Geddes J.R., Higgins J.P., Churchill R., Watanabe N., Nakagawa A., Omori I.M., McGuire H., Tansella M., Barbui C. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009, 373:746-758.
3. Demyttenaere K., Enzlin P., Dewé W., Boulanger B., De Bie J., De Troyer W., Mesters P. Compliance with antidepressants in a primary care setting, 1: beyond lack of efficacy and adverse events. J. Clin. Psychiatry 2001, 62(Suppl 22):30-33.
4. Demyttenaere K., Verhaeghen A., Dantchev N., Grassi L., Montejo A.L., Perahia D.G., Quail D., Reed C., Tylee A., Bauer M. "Caseness" for depression and anxiety in a depressed outpatient population: symptomatic outcome as a function of baseline diagnostic categories. Prim. Care Companion J. Clin. Psychiatry 2009, 11(6):307-315.
5. European Marketing Authorization Valdoxan (Agomelatine): Summary of Product Characteristics 2009.
6. Fournier J.C., DeRubeis R.J., Hollon S.D., Dimidjian S., Amsterdam J.D., Shelton R.C., Fawcett J. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 2010, 303(1):47-53.
7. Gartlehner G., Gaynes B.N. Are all antidepressants equal?. Evid. Based Ment. Health 2009, 12(4):98-100.
8. Gartlehner G., Hansen R.A. Are some antidepressants better than others?. Nat. Rev. Neurol. 2009, 5:239-240.
9. Goethe J.W., Woolley S.B., Cardoni A.A., Woznicki B.A., Piez D.A. Selective serotonin reuptake inhibitor discontinuation: side effects and other factors that influence medication adherence. J. Clin. Psychopharmacol. 2007, 27(5):451-458.
10. Goodwin G.M., Emsley R., Rembry S., Rouillon F., Agomelatine Study Group Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 2009, 70:1128-1137.
11. Hale A., Corral R.M., Mencacci C., Ruiz J.S., Severo C.A., Gentil V. Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study. Int. Clin. Psychopharmacol. 2010, 25:305-314.
12. Kasper S., Hajak G., Wulff K., Hoogendijk W.J., Montejo A.L., Smeraldi E., Rybakowski J.K., Quera-Salva M.A., Wirz-Justice A.M., Picarel-Blanchot F., Baylé F.J. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. J. Clin. Psychiatry 2010, 71:109-120.
13. Katz M.M., Bowden C.L., Frazer A. Rethinking depression and the actions of antidepressants: uncovering the links between the neural and behavioral elements. J. Affect. Disorders 2010, 120:16-23.
14. Kennedy S.H., Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur. Neuropsychopharmacol. 2006, 16(2):93-100.
15. Kennedy S.H., Rizvi S.J. Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness. CNS Drugs 2010, 24(6):479-499.
16. Kennedy S.H., Rizvi S., Fulton Kari, Rasmussen J. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J. Clin. Psychopharmacol. 2008, 28:329-333.
17. Kennedy S.H., Andersen H.F., Thase M.E. Escitalopram in the treatment of major depressive disorder: a meta-analysis. Curr. Med. Res. Opin. 2009, 25(1):161-175.
18. Kirsch I., Deacon B.J., Huedo-Medina T.B., Scoboria A., Moore T.J., Johnson B.T. 2008 initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008, 5(2):e45.
19. Lam R., Andersen N.H. The influence of baseline severity on efficacy of escitalopram and citalopram in the treatment of major depressive disorder: an extended analysis. Pharmacopsychiatry 2006, 39:180-184.
20. Lemoine P., Guilleminault C., Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J. Clin. Psychiatry 2007, 68:1723-1732.
21. Loo H., Hale A., D'Haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int. Clin. Psychopharmacol. 2002, 17:239-247.
22. Melander H., Salmonson T., Abadie E., van Zwieten-Boot B. A regulatory Apologia- a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants. Eur. Neuropsychopharmacol. 2008, 18:623-627.
23. Montejo A.L., Prieto N., Terleira A., Matias J., Alonso S., Paniagua G., Naval S., Parra D.G., Gabriel C., Mocaër E., Portolés A. Better sexual acceptability of agomelatine (25 and 50mg) compared with paroxetine (20mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale. J. Psychopharmacol. 2010, 24:111-120.
24. Nelson J.C., Portera L., Leon A.C. Residual symptoms in depressed patients after treatment with fluoxetine or reboxetine. J. Clin. Psychiatry 2005, 66(11):1409-1414.
25. 2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int. J. Neuropsychopharmacol. 2007, 10:661-673.
26. Papakostas G.I., Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur. Neuropsychopharmacol. 2009, 19(1):34-40.
27. Papakostas G.I., Fava M., Thase M.E. Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches. Biol. Psychiatry 2008, 63(7):699-704.
28. Serna M.C., Cruz I., Real J., Gascó E., Galván L. Duration and adherence of antidepressant treatment (2003 to 2007) based on prescription database. Eur. Psychiatry 2010, 25(4):206-213.
29. Sheehan D.V., Keene M.S., Eaddy M., Krulewicz S., Kraus J.E., Carpenter D.J. Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders. CNS Drugs 2008, 22(11):963-973.
30. Stahl S.M., Fava M., Trivedi M.H., Caputo A., Shah A., Post A. Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial. J. Clin. Psychiatry 2010, 71:616-626.
31. Trivedi M.H., Rush A.J., Wisniewski S.R., Nierenberg A.A., Warden D., Ritz L., Norquist G., Howland R.H., Lebowitz B., McGrath P.J., Shores-Wilson K., Biggs M.M., Balasubramani G.K., Fava M., STAR*D Study Team Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry 2006, 163:28-40.
32. Wisniewski S.R., Rush A.J., Nierenberg A.A., Gaynes B.N., Warden D., Luther J.F., McGrath P.J., Lavori P.W., Thase M.E., Fava M., Trivedi M.H. Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report. Am. J. Psychiatry 2009, 166(5):599-607.
33. Zajecka J., Schatzberg A., Stahl S., Shah A., Caputo A., Post A. Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J. Clin. Psychopharmacol. 2010, 30:135-144.
34. Zimmerman M., Mattia J.I., Posternak M.A. Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice?. Am. J. Psychiatry 2002, 159(3):469-473.
35. Zimmerman M., Posternak M., Friedman M., et al. Which factors influence psychiatrists' selection of antidepressants?. Am. J. Psychiatry 2004, 161:1285-1289.